Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Breast Cancer
Higher HER2 Expression Leads to Better Outcomes with T-DM1 in Patients with Metastatic Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2013, Vol 4, No 4
Washington, DC—Among women with HER2-positive metastatic breast cancer, patients with the highest expression of HER2 had the best outcomes in treatment with ado-trastuzumab emtansine (T-DM1; Kadcyla), according to a biomarker analysis of the phase 3 EMILIA trial which was presented at the 2013 American Association for Cancer Research annual meeting.
Read Article
Tumor Subtype Fails to Explain Racial Disparity in Breast Cancer Survival
By
Charles Bankhead
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2013, Vol 4, No 4
Read Article
HDAC Inhibitor plus PARP Inhibitor or Cisplatin Induce Apoptosis of Triple-Negative Breast Cancer Cells
By
Caroline Helwick
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2013, Highlights
Histone deacetylase (HDAC) inhibitors may have a future in the targeted treatment of triple-negative breast cancer, if the results of in vitro studies can be replicated clinically.
Read Article
Eribulin Plus Trastuzumab an Effective Combination
By
Caroline Helwick
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2013, Highlights
Eribulin mesylate (Halaven) is currently used in patients with metastatic breast cancer whose disease has progressed on other treatments, but the drug may be useful in earlier lines of therapy.
Read Article
HER2 Mutations May Become New Treatment Targets
By
Caroline Helwick
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2013, Highlights
Some patients who test HER2 negative by conventional tests may still benefit from anti-HER2 agents. This is the conclusion of a study that examined HER2 mutations in detail which was presented by Ron Bose, MD, PhD, Assistant Professor, Oncology Division, Department of Medicine, Washington University School of Medicine in St Louis, MO.
Read Article
Results of Immunohistochemistry and In Situ Hybridization Reliable Indicators of HER2-Positive Status
By
Susan Reckling
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2013, Highlights
The incidence of false-negative immunohistochemistry (IHC) is only 1% in patients with primary breast cancer, according to a prospective multicenter Canadian study presented at the meeting.
Read Article
One Year of Trastuzumab Remains the Standard of Care
By
Caroline Helwick
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2013, Highlights
For patients with HER2-positive early breast cancer, 1 year of treatment with trastuzumab (Herceptin) remains the standard of care, according to the HERA trial and a subanalysis of the PHARE study.
Read Article
HER2 Status Determined by Central Laboratory Testing May Be More Reliable than Routine Local Testing
By
Susan Reckling
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2013, Highlights
Determining HER2 status utilizing novel central laboratory testing techniques has been shown to be more reliable than routine local HER2 testing, such as immunohistochemistry or in situ hybridization.
Read Article
Targetable Pathways Revealed for Triple-Negative Breast Cancer
By
Audrey Andrews
Breast Cancer
,
Solid Tumors
March 2013, Highlights
>The molecular make-up of triple- negative breast cancer is becoming better understood, and new evidence suggests that the main biologic pathways can be targeted with drugs, according to Justin Balko, PharmD, PhD, Postdoctoral Research Fellow and Researcher, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville.
Read Article
Real-World Evidence Shows Impact of Musculoskeletal Toxicity of Aromatase Inhibitors on Women with Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
February 2013, Vol 4, No 2
San Antonio, TX—Studies have suggested that musculoskeletal toxicity associated with aromatase inhibitor therapy can lead to noncompliance in up to 33% of women with breast cancer. A new, large cohort study at a single regional cancer center showed that the rate of musculoskeletal toxicity in women with early breast cancer who were treated with endocrine therapy was 64%.
Read Article
Page 11 of 13
4
5
6
7
8
9
10
11
12
13
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma